Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2012 07:30 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Acquires Exclusive U.S. Rights to Chiesi Farmaceutici S.p.A.'s BETHKIS(R) (Tobramycin Inhalation Solution)

CARY, NC--(Marketwire - Nov 8, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty...
November 08, 2012 07:15 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Reports Third Quarter 2012 Financial Results

CARY, NC--(Marketwire - Nov 8, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) Net product sales increased 49% year over year Net income increased...
November 07, 2012 08:47 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Announces Alastair McEwan as Chief Financial Officer

CARY, NC--(Marketwire - Nov 7, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty...
November 01, 2012 18:00 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics to Host Third Quarter 2012 Conference Call

CARY, NC--(Marketwire - Nov 1, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, November 8, 2012, to discuss its...
November 01, 2012 08:40 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Receives Complete Response Letter From the FDA for Lixivaptan

CARY, NC--(Marketwire - Nov 1, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty...
September 13, 2012 13:28 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Provides Update on FDA Advisory Committee Discussion of Lixivaptan

CARY, NC--(Marketwire - Sep 13, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty...
August 09, 2012 07:00 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Reports Second Quarter 2012 Financial Results

CARY, NC--(Marketwire - Aug 9, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) Closes acquisition of EKR Therapeutics, expanding hospital product portfolio and...
August 02, 2012 08:00 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics to Host Second Quarter 2012 Conference Call

CARY, NC--(Marketwire - Aug 2, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, August 9, 2012, to discuss its...
July 25, 2012 08:30 ET | Source: Cornerstone Therapeutics

Cornerstone Therapeutics Announces FDA Advisory Committee to Review Lixivaptan for Treatment of Hyponatremia

CARY, NC--(Marketwire - Jul 25, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products...
July 02, 2012 08:03 ET | Source: Cornerstone Therapeutics

FDA Approves Cornerstone Therapeutics' ANDA for Generic Tussionex(R) Pennkinetic(R) Product

CARY, NC--(Marketwire - Jul 2, 2012) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products for...